Using a publically available gene expression study comparing unstimulated CD8+ T cells to CD3/CD28 antibody and IL-2-activated T cells (Wang et al, 2008), we indeed identified overlapping gene signatures in both these studies (Supplementary Fig S6B), suggesting that CCR9 knockdown on tumor cells favors better survival, proliferation, and activation of the encountering T cells. The gene discussed is CD28; the disease is neoplasm.